Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04928170

The Halland Osteoarthritis Cohort

Osteoarthritis is the most common musculoskeletal disease and is characterized by cartilage destruction, osteophyte formation, subchondral bone sclerosis and cysts. Modern treatment strategies, as well as preventive measures, include early detection and knowledge of the early course of the disease. This includes how stress patterns, physical activity, impaired function and metabolic changes and other comorbidities affect development and possible associations with osteoarthritis.

The overall objective was to study the early development of osteoarthritis of the knee and its association with hand- and general osteoarthritis, metabolic diseases, biomarkers, long-term pain, physical function and stress patterns

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Osteoarthritis, Knee Arthritis Joint Diseases Musculoskeletal Diseases Osteoarthritis Osteoarthritis Generalized Osteoarthritis Hand Rheumatic Diseases

Age range

30 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Spenshult Research and Development center (FoU Spenshult)

Halmstad, SE-30274, Sweden

About this study

The overall objective was to study the early development of osteoarthritis of the knee and its association with hand- and general osteoarthritis, metabolic diseases, biomarkers, long-term pain, physical function and stress patterns.

The project includes 4 different research areas that are studied with the help of several smaller sub-studies:

Research area 1: Metabolic osteoarthritis - to study the connections between metabolic factors and osteoarthritis development in the knee and hand.

A. Relationship between knee osteoarthritis and metabolic factors B. Relationship between osteoarthritis of the hand and metabolic factors Research area 2: Biomarkers in knee and hand osteoarthritis - to study cartilage and bone markers that reflect different processes in osteoarthritis development, e.g. inflammation, matrix degradation both in the short and long term Research area 3: Pain and osteoarthritis - to study pain development and pain pressure thresholds in relation to lifestyle, depression and health-related quality of life in individuals with symptomatic knee osteoarthritis Research area 4: Physical function and osteoarthritis - to study physical function, physical activity and measured stress patterns, as well as changes in stress patterns and the relationship between these and the development of osteoarthritis over time.

Study design This is a longitudinal cohort study including 306 individuals with knee pain in the southwest of Sweden, the Halland osteoarthritis (HALLOA) cohort. The enrolments took place from 2017-2019. The participants were recruited: 1) by primary health care clinics when searching care for knee pain, or 2) by advertisements in local newspapers. The inclusion criterions were current knee pain, aged 30-65 years, with no former known radiographic knee osteoarthritis (RKOA). the exclusion criterions were no cruciate ligament rupture or rheumatologic disorder. A general practitioner examined all participants to confirm the exclusion criteria.

The cohort will be followed for five years with yearly follow-ups.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Knee pain

Exclusion criteria

Cruciate ligament injury and rheumatic disease (RA, PsoA, As, Sponylarthritis etc)

Treatment and study plan

Primary outcomes

  1. BMI (kg/m2)

    Time frame: At baseline

    weight (kg) and height (m) are meassured and BMI will be calculated

  2. BMI (kg/m2)

    Time frame: At 2 years follow-up

    weight (kg) and height (m) are meassured and BMI will be calculated

  3. BMI (kg/m2)

    Time frame: At 5 years follow-up

    weight (kg) and height (m) are meassured and BMI will be calculated

  4. Abdominal circumference (cm)

    Time frame: At baseline

    Abdominal circumference are meassured with measuring tape at navel height

  5. Abdominal circumference (cm)

    Time frame: At 2 years follow-up

    Abdominal circumference are meassured with measuring tape at navel height

  6. Abdominal circumference (cm)

    Time frame: At 5 years follow-up

    Abdominal circumference are meassured with measuring tape at navel height

  7. Body composition

    Time frame: At baseline

    Body composition are assessed by Inbody 770, which gives data on proportion of muscle and body fat (separate meassures on visceral fat

  8. Body composition

    Time frame: At 2 years follow-up

    Body composition are assessed by Inbody 770, which gives data on proportion of muscle and body fat (separate meassures on visceral fat

  9. Body composition

    Time frame: At 5 years follow-up

    Body composition are assessed by Inbody 770, which gives data on proportion of muscle and body fat (separate meassures on visceral fat

  10. Glucos

    Time frame: At Baseline

    Fasting glucos (mmol/L) meassured in serum

  11. Glucos

    Time frame: At 1 year follow-up

    Fasting glucos (mmol/L) meassured in serum

  12. Glucos

    Time frame: At 2 years follow-up

    Fasting glucos (mmol/L) meassured in serum

  13. Glucos

    Time frame: At 3 years follow-up

    Fasting glucos (mmol/L) meassured in serum

  14. Glucos

    Time frame: At 4 years follow-up

    Fasting glucos (mmol/L) meassured in serum

  15. Glucos

    Time frame: At 5 years follow-up

    Fasting glucos (mmol/L) meassured in serum

  16. HbA1c

    Time frame: At baseline

    HbA1c (mmol/mol) meassured in serum

  17. HbA1c

    Time frame: At 1 year follow-up

    HbA1c (mmol/mol) meassured in serum

  18. HbA1c

    Time frame: At 2 years follow-up

    HbA1c (mmol/mol) meassured in serum

  19. HbA1c

    Time frame: At 3 years follow-up

    HbA1c (mmol/mol) meassured in serum

  20. HbA1c

    Time frame: At 4 years follow-up

    HbA1c (mmol/mol) meassured in serum

  21. HbA1c

    Time frame: At 5 years follow-up

    HbA1c (mmol/mol) meassured in serum

  22. Total-cholesterol

    Time frame: At baseline

    Total-cholesterol (mmol/L) meassured in serum

  23. Total-cholesterol

    Time frame: At 1 year follow-up

    Total-cholesterol (mmol/L) meassured in serum

  24. Total-cholesterol

    Time frame: At 2 years follow-up

    Total-cholesterol (mmol/L) meassured in serum

  25. Total-cholesterol

    Time frame: At 3 years follow-up

    Total-cholesterol (mmol/L) meassured in serum

  26. Total-cholesterol

    Time frame: At 4 years follow-up

    Total-cholesterol (mmol/L) meassured in serum

  27. Total-cholesterol

    Time frame: At 5 years follow-up

    Total-cholesterol (mmol/L) meassured in serum

  28. Triglycerides

    Time frame: At baseline

    Triglycerides (mmol/L) meassured in serum

  29. Triglycerides

    Time frame: At 1 year follow-up

    Triglycerides (mmol/L) meassured in serum

  30. Triglycerides

    Time frame: At 2 years follow-up

    Triglycerides (mmol/L) meassured in serum

  31. Triglycerides

    Time frame: At 3 years follow-up

    Triglycerides (mmol/L) meassured in serum

  32. Triglycerides

    Time frame: At 4 years follow-up

    Triglycerides (mmol/L) meassured in serum

  33. Triglycerides

    Time frame: At 5 years follow-up

    Triglycerides (mmol/L) meassured in serum

  34. LDL-cholesterol

    Time frame: At baseline

    LDL-cholesterol (mmol/L) meassured in serum

  35. LDL-cholesterol

    Time frame: At 1 year follow-up

    LDL-cholesterol (mmol/L) meassured in serum

  36. LDL-cholesterol

    Time frame: At 2 years follow-up

    LDL-cholesterol (mmol/L) meassured in serum

  37. LDL-cholesterol

    Time frame: At 3 years follow-up

    LDL-cholesterol (mmol/L) meassured in serum

  38. LDL-cholesterol

    Time frame: At 4 years follow-up

    LDL-cholesterol (mmol/L) meassured in serum

  39. LDL-cholesterol

    Time frame: At 5 years follow-up

    LDL-cholesterol (mmol/L) meassured in serum

  40. HDL-cholesterol

    Time frame: At baseline

    HDL-cholesterol (mmol/L) meassured in serum

  41. HDL-cholesterol

    Time frame: At 1 year follow-up

    HDL-cholesterol (mmol/L) meassured in serum

  42. HDL-cholesterol

    Time frame: At 2 years follow-up

    HDL-cholesterol (mmol/L) meassured in serum

  43. HDL-cholesterol

    Time frame: At 3 years follow-up

    HDL-cholesterol (mmol/L) meassured in serum

  44. HDL-cholesterol

    Time frame: At 4 years follow-up

    HDL-cholesterol (mmol/L) meassured in serum

  45. HDL-cholesterol

    Time frame: At 5 years follow-up

    HDL-cholesterol (mmol/L) meassured in serum

  46. Sensitive C-Reactive Protein (CRP)

    Time frame: At baseline

    sensitive CRP (g/L) meassured in serum

  47. Sensitive C-Reactive Protein (CRP)

    Time frame: At 1 year follow-up

    sensitive CRP (g/L) meassured in serum

  48. Sensitive C-Reactive Protein (CRP)

    Time frame: At 2 years follow-up

    sensitive CRP (g/L) meassured in serum

  49. Sensitive C-Reactive Protein (CRP)

    Time frame: At 3 years follow-up

    sensitive CRP (g/L) meassured in serum

  50. Sensitive C-Reactive Protein (CRP)

    Time frame: At 4 years follow-up

    sensitive CRP (g/L) meassured in serum

  51. Sensitive C-Reactive Protein (CRP)

    Time frame: At 5 years follow-up

    sensitive CRP (g/L) meassured in serum

  52. Interleukin-1 (IL-1)

    Time frame: At baseline

    IL-1 (pg/mL) meassured in plasma with ELISA

  53. Interleukin-1 (IL-1)

    Time frame: At 1 year follow-up

    IL-1 (pg/mL) meassured in plasma with ELISA

  54. Interleukin-1 (IL-1)

    Time frame: At 2 years follow-up

    IL-1 (pg/mL) meassured in plasma with ELISA

  55. Interleukin-1 (IL-1)

    Time frame: At 3 years follow-up

    IL-1 (pg/mL) meassured in plasma with ELISA

  56. Interleukin-1 (IL-1)

    Time frame: At 4 years follow-up

    IL-1 (pg/mL) meassured in plasma with ELISA

  57. Interleukin-1 (IL-1)

    Time frame: At 5 years follow-up

    IL-1 (pg/mL) meassured in plasma with ELISA

  58. Interleukin-6 (IL-6)

    Time frame: At baseline

    IL-6 (pg/mL) meassured in plasma with ELISA

  59. Interleukin-6 (IL-6)

    Time frame: At 1 year follow-up

    IL-6 (pg/mL) meassured in plasma with ELISA

  60. Interleukin-6 (IL-6)

    Time frame: At 2 years follow-up

    IL-6 (pg/mL) meassured in plasma with ELISA

  61. Interleukin-6 (IL-6)

    Time frame: At 3 years follow-up

    IL-6 (pg/mL) meassured in plasma with ELISA

  62. Interleukin-6 (IL-6)

    Time frame: At 4 years follow-up

    IL-6 (pg/mL) meassured in plasma with ELISA

  63. Interleukin-6 (IL-6)

    Time frame: At 5 years follow-up

    IL-6 (pg/mL) meassured in plasma with ELISA

  64. Tumor Necrosis Factor-alfa (TNF-alfa)

    Time frame: At baseline

    TNF-alfa (pg/mL) meassured in plasma with ELISA

  65. Tumor Necrosis Factor-alfa (TNF-alfa)

    Time frame: At 1 year follow-up

    TNF-alfa (pg/mL) meassured in plasma with ELISA

  66. Tumor Necrosis Factor-alfa (TNF-alfa)

    Time frame: At 2 years follow-up

    TNF-alfa (pg/mL) meassured in plasma with ELISA

  67. Tumor Necrosis Factor-alfa (TNF-alfa)

    Time frame: At 3 years folllow-up

    TNF-alfa (pg/mL) meassured in plasma with ELISA

  68. Tumor Necrosis Factor-alfa (TNF-alfa)

    Time frame: At 4 years follow-up

    TNF-alfa (pg/mL) meassured in plasma with ELISA

  69. Tumor Necrosis Factor-alfa (TNF-alfa)

    Time frame: At 5 years follow-up

    TNF-alfa (pg/mL) meassured in plasma with ELISA

  70. Leptin

    Time frame: At baseline

    Leptin (ng/mL) meassured in serum with ELISA

  71. Leptin

    Time frame: At 1 year follow-up

    Leptin (ng/mL) meassured in serum with ELISA

  72. Leptin

    Time frame: At 2 years follow-up

    Leptin (ng/mL) meassured in serum with ELISA

  73. Leptin

    Time frame: At 3 years follow-up

    Leptin (ng/mL) meassured in serum with ELISA

  74. Leptin

    Time frame: At 4 years follow-up

    Leptin (ng/mL) meassured in serum with ELISA

  75. Leptin

    Time frame: At 5 years follow-up

    Leptin (ng/mL) meassured in serum with ELISA

  76. Galectin-1

    Time frame: At baseline

    Galectin-1 (ng/mL) meassured in plasma with ELISA

  77. Galectin-1

    Time frame: At 1 year follow-up

    Galectin-1 (ng/mL) meassured in plasma with ELISA

  78. Galectin-1

    Time frame: At 2 years follow-up

    Galectin-1 (ng/mL) meassured in plasma with ELISA

  79. Galectin-1

    Time frame: At 3 years follow-up

    Galectin-1 (ng/mL) meassured in plasma with ELISA

  80. Galectin-1

    Time frame: At 4 years follow-up

    Galectin-1 (ng/mL) meassured in plasma with ELISA

  81. Galectin-1

    Time frame: At 5 years follow-up

    Galectin-1 (ng/mL) meassured in plasma with ELISA

  82. One-leg rise

    Time frame: At baseline

    Knee strenght are assessed by one-leg rise

  83. One-leg rise

    Time frame: At 2 years follow-up

    Knee strenght are assessed by one-leg rise

  84. One-leg rise

    Time frame: At 5 years follow-up

    Knee strenght are assessed by one-leg rise

  85. 30s-chair stand test

    Time frame: At baseline

    Knee strenght are assessed by 30s-chair stand test

  86. 30s-chair stand test

    Time frame: At 2 years follow-up

    Knee strenght are assessed by 30s-chair stand test

  87. 30s-chair stand test

    Time frame: At 5 years follow-up

    Knee strenght are assessed by 30s-chair stand test

  88. Maximal voluntary isometric contraction of Quadriceps

    Time frame: At baseline

    Maximal voluntary isometric contraction of Quadriceps assessed by dynamometer (N)

  89. Maximal voluntary isometric contraction of Quadriceps

    Time frame: At 2 years follow-up

    Maximal voluntary isometric contraction of Quadriceps assessed by dynamometer (N)

  90. Maximal voluntary isometric contraction of Quadriceps

    Time frame: At 5 years follow-up

    Maximal voluntary isometric contraction of Quadriceps assessed by dynamometer (N)

  91. Hand strenght

    Time frame: At baseline

    Hand strenght are assessed by grippit (N)

  92. Hand strenght

    Time frame: At 2 years follow-up

    Hand strenght are assessed by grippit (N)

  93. Hand strenght

    Time frame: At 5 years follow-up

    Hand strenght are assessed by grippit (N)

  94. Fitness

    Time frame: At 2 years follow-up

    Fitness are assessed by Åstrands test

  95. Fitness

    Time frame: At 5 years follow-up

    Fitness are assessed by Åstrands test

  96. Pain thresholds

    Time frame: At baseline

    pain threshold are assesed by computerized pressure algometry on eight predefined tender points out of the 18 points as part of the definition of fibromyalgia

  97. Pain thresholds

    Time frame: At 2 years follow-up

    pain threshold are assesed by computerized pressure algometry on eight predefined tender points out of the 18 points as part of the definition of fibromyalgia

  98. Pain thresholds

    Time frame: At 5 years follow-up

    pain threshold are assesed by computerized pressure algometry on eight predefined tender points out of the 18 points as part of the definition of fibromyalgia

  99. Knee injury and osteoarthritis outcome score (KOOS)

    Time frame: At baseline

    KOOS consists of 5 subscales, assessing self reported knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).

  100. Knee injury and osteoarthritis outcome score (KOOS)

    Time frame: At 1 year follow-up

    KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).

  101. Knee injury and osteoarthritis outcome score (KOOS)

    Time frame: At 2 years follow-up

    KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).

  102. Knee injury and osteoarthritis outcome score (KOOS)

    Time frame: At 3 years follow-up

    KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).

  103. Knee injury and osteoarthritis outcome score (KOOS)

    Time frame: At 4 years follow-up

    KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).

  104. Knee injury and osteoarthritis outcome score (KOOS)

    Time frame: At 5 years follow-up

    KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).

  105. Pain mannequin

    Time frame: At baseline

    Patient reported pain distribution

  106. Pain mannequin

    Time frame: At 1 year follow-up

    Patient reported pain distribution

  107. Pain mannequin

    Time frame: At 2 years follow-up

    Patient reported pain distribution

  108. Pain mannequin

    Time frame: At 3 years follow-up

    Patient reported pain distribution

  109. Pain mannequin

    Time frame: At 4 years follow-up

    Patient reported pain distribution

  110. Pain mannequin

    Time frame: At 5 years follow-up

    Patient reported pain distribution

  111. Pain intensity

    Time frame: At baseline

    Patient reported pain intensity by NRS scale 0-10 (best to worst)

  112. Pain intensity

    Time frame: At 1 year follow-up

    Patient reported pain intensity by NRS scale 0-10 (best to worst)

  113. Pain intensity

    Time frame: At 2 years follow-up

    Patient reported pain intensity by NRS scale 0-10 (best to worst)

  114. Pain intensity

    Time frame: At 3 years follow-up

    Patient reported pain intensity by NRS scale 0-10 (best to worst)

  115. Pain intensity

    Time frame: At 4 years follow-up

    Patient reported pain intensity by NRS scale 0-10 (best to worst)

  116. Patient intensity

    Time frame: At 5 years follow-up

    Patient reported pain intensity by NRS scale 0-10 (best to worst)

  117. Radiographic assessment of the knees

    Time frame: At baseline

    radiographic assessment of tibiofemoral- and patellofemoral joint in the knee

  118. Radiographic assessment of the knees

    Time frame: At 1 year follow-up

    radiographic assessment of tibiofemoral- and patellofemoral joint in the knee

  119. Radiographic assessment of the knees

    Time frame: At 2 years follow-up

    radiographic assessment of tibiofemoral- and patellofemoral joint in the knee

  120. Radiographic assessment of the knees

    Time frame: At 3 years follow-up

    radiographic assessment of tibiofemoral- and patellofemoral joint in the knee

  121. Radiographic assessment of the knees

    Time frame: At 4 years follow-up

    radiographic assessment of tibiofemoral- and patellofemoral joint in the knee

  122. Radiographic assessment of the knees

    Time frame: At 5 years follow-up

    radiographic assessment of tibiofemoral- and patellofemoral joint in the knee

  123. Radiographic assessment of the hands

    Time frame: At 2 years follow-up

    Radiographic assessment of the hands.

  124. Radiographic assessment of the hands

    Time frame: At 5 years follow-up

    Radiographic assessment of the hands.

  125. Mechanical load

    Time frame: At inclusion

    Movement behavior measured with a triaxle accelerometer at work and leisure over 7 days

  126. Mechanical load

    Time frame: At 2 years follow-up

    Movement behavior measured with a triaxle accelerometer at work and leisure over 7 days

  127. Mechanical load

    Time frame: At 5 years follow-up

    Movement behavior measured with a triaxle accelerometer at work and leisure over 7 days

Secondary outcomes

  1. Blood samples for biobanking

    Time frame: At baseline

    serum and plasma for biobanking in -70 degrees celcius

  2. Blood samples for biobanking

    Time frame: At 1 year follow-up

    serum and plasma for biobanking in -70 degrees celcius

  3. Blood samples for biobanking

    Time frame: At 2 years follow-up

    serum and plasma for biobanking in -70 degrees celcius

  4. Blood samples for biobanking

    Time frame: At 3 years follow-up

    serum and plasma for biobanking in -70 degrees celcius

  5. Blood samples for biobanking

    Time frame: At 4 years follow-up

    serum and plasma for biobanking in -70 degrees celcius

  6. Blood samples for biobanking

    Time frame: At 5 years follow-up

    serum and plasma for biobanking in -70 degrees celcius

  7. Patient reported physical activity

    Time frame: At baseline

    Patient reported physical activity with questions duration and intensity according to WHO recommendations

  8. Patient reported physical activity

    Time frame: At 1 year follow-up

    Patient reported physical activity with questions duration and intensity according to WHO recommendations

  9. Patient reported physical activity

    Time frame: At 2 years follow-up

    Patient reported physical activity with questions duration and intensity according to WHO recommendations

  10. Patient reported physical activity

    Time frame: At 3 years follow-up

    Patient reported physical activity with questions duration and intensity according to WHO recommendations

  11. Patient reported physical activity

    Time frame: At 4 years follow-up

    Patient reported physical activity with questions duration and intensity according to WHO recommendations

  12. Patient reported physical activity

    Time frame: At 5 years follow-up

    Patient reported physical activity with questions duration and intensity according to WHO recommendations

  13. Patient reported smoking and snuff habits

    Time frame: At baseline

    Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff

  14. Patient reported smoking and snuff habits

    Time frame: At 1 years follow-up

    Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff

  15. Patient reported smoking and snuff habits

    Time frame: At 2 years follow-up

    Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff

  16. Patient reported smoking and snuff habits

    Time frame: At 3 years follow-up

    Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff

  17. Patient reported smoking and snuff habits

    Time frame: At 4 years follow-up

    Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff

  18. Patient reported smoking and snuff habits

    Time frame: At 5 years follow-up

    Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff

  19. Patient reported diets

    Time frame: At baseline

    Patient reported diets and intake of fruits and sweets

  20. Patient reported diets

    Time frame: At 1 year follow-up

    Patient reported diets and intake of fruits and sweets

  21. Patient reported diets

    Time frame: At 2 years follow-up

    Patient reported diets and intake of fruits and sweets

  22. Patient reported diets

    Time frame: At 3 years follow-up

    Patient reported diets and intake of fruits and sweets

  23. Patient reported diets

    Time frame: At 4 years follow-up

    Patient reported diets and intake of fruits and sweets

  24. Patient reported diets

    Time frame: At 5 years follow-up

    Patient reported diets and intake of fruits and sweets

  25. Patient reported alcohol habits

    Time frame: At baseline

    Patient reported alcohol habis assessed by AUDIT C

  26. Patient reported alcohol habits

    Time frame: At 1 year follow-up

    Patient reported alcohol habis assessed by AUDIT C

  27. Patient reported alcohol habits

    Time frame: At 2 years follow-up

    Patient reported alcohol habis assessed by AUDIT C

  28. Patient reported alcohol habits

    Time frame: At 3 years follow-up

    Patient reported alcohol habis assessed by AUDIT C

  29. Patient reported alcohol habits

    Time frame: At 4 years follow-up

    Patient reported alcohol habis assessed by AUDIT C

  30. Patient reported alcohol habits

    Time frame: At 5 years follow-up

    Patient reported alcohol habis assessed by AUDIT C

  31. Hospital Anxiety and Depression Scale (HADS)

    Time frame: At baseline

    HADS is a simple self-assessment form that shows a measure of the patient's mood.

  32. Hospital Anxiety and Depression Scale (HADS)

    Time frame: At 1 year follow-up

    HADS is a simple self-assessment form that shows a measure of the patient's mood.

  33. Hospital Anxiety and Depression Scale (HADS)

    Time frame: At 2 years follow-up

    HADS is a simple self-assessment form that shows a measure of the patient's mood.

  34. Hospital Anxiety and Depression Scale (HADS)

    Time frame: At 3 years follow-up

    HADS is a simple self-assessment form that shows a measure of the patient's mood.

  35. Hospital Anxiety and Depression Scale (HADS)

    Time frame: At 4 years follow-up

    HADS is a simple self-assessment form that shows a measure of the patient's mood.

  36. Hospital Anxiety and Depression Scale (HADS)

    Time frame: At 5 years follow-up

    HADS is a simple self-assessment form that shows a measure of the patient's mood.

  37. Health literacy

    Time frame: At 2 years follow-up

    Health literacy assessed with the Swedish Functional Health Literacy scale

  38. Health literacy

    Time frame: At 3 years follow-up

    Health literacy assessed with the Swedish Functional Health Literacy scale

  39. Health literacy

    Time frame: At 5 years follow-up

    Health literacy assessed with the Swedish Functional Health Literacy scale

  40. Clinical examination of the knees

    Time frame: At baseline

    Clinical examination to assessing clinical knee OA

  41. Clinical examination of the knees

    Time frame: At 2 years follow-up

    Clinical examination to assessing clinical knee OA

  42. Clinical examination of the knees

    Time frame: At 5 years follow-up

    Clinical examination to assessing clinical knee OA

  43. Clinical examination of the hands

    Time frame: At baseline

    Clinical examination of the hands assessing clinical hand OA

  44. Clinical examination of the hands

    Time frame: At 2 years follow-up

    Clinical examination of the hands assessing clinical hand OA

  45. Clinical examination of the hands

    Time frame: At 5 years follow-up

    Clinical examination of the hands assessing clinical hand OA

  46. Blood pressure

    Time frame: At baseline

    Blood pressure assessed in sitting position after rest, mmHg

  47. Blood pressure

    Time frame: At 2 years follow-up

    Blood pressure assessed in sitting position after rest, mmHg

  48. Blood pressure

    Time frame: At 5 years follow-up

    Blood pressure assessed in sitting position after rest, mmHg

Sponsors and collaborators

Lead sponsor

FoU Center Spenshult

Other

Collaborators

  • The Swedish Rheumatism Ass

Registry information

Official study title

The Halland Osteoarthritis (HALLOA) Cohort Study - a Five-year Observational Longitudinal Study With Focus on Metabolic Osteoarthritis

Acronym: HALLOA

Important dates

Study start
2016
Primary completion
2019
Study completion
2024
First posted
Jun 16, 2021
Registry last updated
Oct 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.